Adverum Biotechnologies, Inc.
ADVM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $39 | $37 | $29 | $24 |
| G&A Expenses | $9 | $13 | $19 | $38 |
| SG&A Expenses | $9 | $13 | $19 | $38 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1 | $0 | $0 | $0 |
| Operating Expenses | $47 | $50 | $48 | $62 |
| Operating Income | -$47 | -$50 | -$48 | -$62 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$1 | $1 | $1 | $2 |
| Pre-Tax Income | -$48 | -$49 | -$47 | -$61 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$48 | -$49 | -$47 | -$61 |
| % Margin | – | – | – | – |
| EPS | -2.03 | -2.34 | -2.25 | -1.96 |
| % Growth | 13.2% | -4% | -14.8% | – |
| EPS Diluted | -2.03 | -2.34 | -2.25 | -1.96 |
| Weighted Avg Shares Out | 23 | 21 | 21 | 21 |
| Weighted Avg Shares Out Dil | 23 | 21 | 21 | 21 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $1 | $1 |
| EBITDA | -$47 | -$49 | -$48 | -$61 |
| % Margin | – | – | – | – |